Analysts at StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Price Performance
Shares of EVOK opened at $5.30 on Friday. The company has a market capitalization of $4.35 million, a PE ratio of -0.33 and a beta of 0.39. Evoke Pharma has a one year low of $3.54 and a one year high of $17.88. The company’s fifty day moving average price is $4.77 and its 200 day moving average price is $5.52.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Evoke Pharma had a negative return on equity of 964.25% and a negative net margin of 86.74%. The business had revenue of $2.55 million during the quarter.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
See Also
- Five stocks we like better than Evoke Pharma
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- High Flyers: 3 Natural Gas Stocks for March 2022
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Why Invest in 5G? How to Invest in 5G Stocks
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
